PL371180A1 - Pyrimidotriazines as phosphatase inhibitors - Google Patents

Pyrimidotriazines as phosphatase inhibitors

Info

Publication number
PL371180A1
PL371180A1 PL02371180A PL37118002A PL371180A1 PL 371180 A1 PL371180 A1 PL 371180A1 PL 02371180 A PL02371180 A PL 02371180A PL 37118002 A PL37118002 A PL 37118002A PL 371180 A1 PL371180 A1 PL 371180A1
Authority
PL
Poland
Prior art keywords
pyrimidotriazines
phosphatase inhibitors
pyrimido
triazine
useful
Prior art date
Application number
PL02371180A
Other languages
Polish (pl)
Inventor
Kevin Richard Guertin
Lina Quattrocchio Setti
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL371180A1 publication Critical patent/PL371180A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B.
PL02371180A 2001-12-27 2002-12-27 Pyrimidotriazines as phosphatase inhibitors PL371180A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34393701P 2001-12-27 2001-12-27
US39911002P 2002-07-26 2002-07-26

Publications (1)

Publication Number Publication Date
PL371180A1 true PL371180A1 (en) 2005-06-13

Family

ID=26993696

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371180A PL371180A1 (en) 2001-12-27 2002-12-27 Pyrimidotriazines as phosphatase inhibitors

Country Status (19)

Country Link
US (1) US6642381B2 (en)
EP (1) EP1467996B1 (en)
JP (1) JP4188839B2 (en)
KR (1) KR100601769B1 (en)
CN (1) CN100402530C (en)
AT (1) ATE311388T1 (en)
AU (1) AU2002367190B2 (en)
BR (1) BR0215395A (en)
CA (1) CA2471265C (en)
DE (1) DE60207759T2 (en)
ES (1) ES2252554T3 (en)
JO (1) JO2242B1 (en)
MX (1) MXPA04006266A (en)
PA (1) PA8562901A1 (en)
PE (1) PE20030896A1 (en)
PL (1) PL371180A1 (en)
TW (1) TW200306313A (en)
UY (1) UY27606A1 (en)
WO (1) WO2003055883A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463615C (en) * 2001-10-30 2011-07-26 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
PL377620A1 (en) 2002-11-18 2006-02-06 F. Hoffmann-La Roche Ag Diazinopyrimidines
WO2004071448A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
JP2006518738A (en) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド Substituted azole derivatives as therapeutic agents
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
AU2007211319B9 (en) 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (en) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010083645A1 (en) * 2009-01-21 2010-07-29 Shanghai Targetdrug Co., Ltd PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
CA2904129A1 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EA201592263A1 (en) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor

Also Published As

Publication number Publication date
AU2002367190A1 (en) 2003-07-15
ATE311388T1 (en) 2005-12-15
EP1467996B1 (en) 2005-11-30
PA8562901A1 (en) 2003-07-28
DE60207759T2 (en) 2006-08-03
PE20030896A1 (en) 2003-11-05
CN1610683A (en) 2005-04-27
KR100601769B1 (en) 2006-07-19
ES2252554T3 (en) 2006-05-16
UY27606A1 (en) 2003-06-30
US6642381B2 (en) 2003-11-04
TW200306313A (en) 2003-11-16
EP1467996A1 (en) 2004-10-20
BR0215395A (en) 2004-12-07
CA2471265C (en) 2010-02-09
AU2002367190B2 (en) 2006-10-05
CA2471265A1 (en) 2003-07-10
DE60207759D1 (en) 2006-01-05
JP4188839B2 (en) 2008-12-03
US20030153756A1 (en) 2003-08-14
MXPA04006266A (en) 2004-09-27
WO2003055883A1 (en) 2003-07-10
JP2005517677A (en) 2005-06-16
KR20040068981A (en) 2004-08-02
JO2242B1 (en) 2004-10-07
CN100402530C (en) 2008-07-16

Similar Documents

Publication Publication Date Title
PA8562901A1 (en) PHOSPHATASE INHIBITORS
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
PL369530A1 (en) Chemical compounds
ATE227567T1 (en) PREPARATIONS FOR INHIBITING BONE RESORPTION MEDIATED BY OSTEOCLASTS
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
TR200000782T2 (en) Resorcinol derivatives.
NO20073801L (en) Atineoplastic combinations
MXPA05011296A (en) Kinase inhibitor phosphonate conjugates.
IL151313A0 (en) Lipase containing pharmaceutical compositions
MXPA04003886A (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents.
MXPA05012026A (en) Azaindole compounds as kinase inhibitors.
PL345993A1 (en) Novel salt form of pantoprazole
SG129448A1 (en) Preparation of 1,3-diphenylprop-2-en-1-one derivatives
MY133390A (en) Azabicyclic 5ht1 receptor ligands
GB9918429D0 (en) Organic compounds
WO2002047604A3 (en) Novel use of chalcone class compounds for inhibiting tumoral mass vascularization
WO2004060878A3 (en) Inhibitors of phosphatases
GB0103045D0 (en) Organic Compounds
PL1628979T3 (en) Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
PL1633754T3 (en) Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
AU2003264707A1 (en) Use of a chrysanthellum extract
MXPA03005400A (en) Method for the preparation of 11(12)-pentadecen-15-olides.
MXPA04004757A (en) Use of an ascomycin for the treatment of blepharitis.
PT1144348E (en) LTA INHIBITORS, HYDROLASE

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)